RxDoctor Payments Data

Brian Anseeuw, MD

Neurology · Moline, ILNPI 1568476117

Payments from drug & device makers

$29,393in general payments, 2019–2025

Across 813 payments — averaging $36.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$19K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Lilly USA, LLC$847
  • Novartis$689
  • Eisai Inc.$675
  • Lundbeck LLC$643
  • plus $6K from 48 others

What the payments were for

  • Speaking & faculty fees$16,86357%
  • Travel & lodging$2761%
  • Food & beverage$12,10441%
  • Education$1521%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,393 in reported general payments places this provider in the 80th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$249,669
Medicare patients
399
Services billed
1,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate29$143,482
Gamunex-CImmune Globul G/Gly/Iga Avg 4614$120,532
VumerityDiroximel Fumarate12$120,209
TecfideraDimethyl Fumarate12$116,793
GammakedImmune Globul G/Gly/Iga Avg 4612$84,203
QuliptaAtogepant35$42,008
Aimovig AutoinjectorErenumab-Aooe46$39,143
Nurtec OdtRimegepant Sulfate22$34,263
TopamaxTopiramate13$29,333
NamzaricMemantine Hcl/Donepezil Hcl40$26,649
UbrelvyUbrogepant18$23,309
NuedextaDextromethorphan Hbr/Quinidine12$19,462
NeuproRotigotine23$19,334
BriviactBrivaracetam12$17,826
Carbidopa-Levodopa ErCarbidopa/Levodopa243$16,608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Tecfidera$559$237,00224 claims
Acadia Pharmaceuticals IncNuplazid$180$143,48229 claims
Grifols USA, LLCGamunex-C$15$120,53214 claims
AbbVieQulipta, Namzaric, Ubrelvy, Botox$19,039$106,459104 claims
Kedrion Biopharma, Inc.Gammaked$13$84,20312 claims
PfizerNurtec Odt, Dilantin$579$37,66333 claims
UCB, Inc.Neupro, Briviact$229$37,16035 claims
Avanir Pharmaceuticals, Inc.Nuedexta$471$19,46212 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$94$3,60192 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 790 neurology providers in Illinois.

Other neurology in Moline

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →